Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which diabetes drug fights fatty liver better? new study pits dapagliflozin against empagliflozin

NCT ID NCT07363707

Disease control Sponsor: Beni-Suef University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed phase 4 trial compared two common diabetes drugs, dapagliflozin and empagliflozin, added to metformin in 108 adults with type 2 diabetes and nonalcoholic fatty liver disease (NAFLD). Participants took one of the two drugs daily for six months. Researchers used liver scans and blood tests to measure changes in liver fat and function, aiming to see which drug works better for NAFLD.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
dapagliflozin and empagliflozin (SGLT2 inhibitors)
What this could lead to
If successful, this study could show which SGLT2 inhibitor is better at reducing liver fat in people with type 2 diabetes and NAFLD, potentially guiding treatment choices.
What could go wrong
This is a small, completed phase 4 trial with only 108 participants, so results may not apply to everyone. The primary outcomes are surrogate markers (liver stiffness and blood tests), not hard endpoints like liver-related illness or death.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

108 people

The number who actually took part.

Started

May 2023

Finished

Mar 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults from 18 years old, male or female type 2 diabetic NAFLD patients. Exclusion Criteria: * People who have chronic liver disease, * Hepatitis C virus (HCV) patients or those treated for HCV, * History of autoimmune disease, * Drugs that cause steatohepatitis * and alcoholic patients will be excluded.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NAFLD - nonalcoholic fatty liver disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatotic liver disease type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NAFLD - nonalcoholic fatty liver disease

Contacts and locations

Locations

  • Beni Suef University Hospital

    Cairo, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.